Naloxone Hcl Spray
Product Images NDC 51662-1620

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Naloxone Hcl (NDC 51662-1620). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pback (51662 1620 1 Package Label Back 3 1)

Close-up of a Naloxone HCl Nasal Spray label showing the 4 mg strength. It indicates use for nasal administration with one spray per device. Storage instructions and manufacturer information (Perrigo, Israel) appear, along with a barcode and NDC 45802-811-00. The label includes the note that the device should not be tested before use.*

FDA Label Image

Front (51662 1620 1 Package Label Front)

Naloxone HCl Nasal Spray 4 mg/.1 mL in clear plastic packaging. The label includes the product name, indication for nasal use, a barcode, and an NDC number different from the provided data, along with branding elements. The nasal spray device is visible inside the packaging.*

FDA Label Image

S1 (51662 1620 1 Serialized Label)

This image shows a label featuring a barcode and human-readable GS1 barcode data for NALOXONE HCl nasal spray, distributed by HF Acquisition Co LLC. It includes identifiers such as a GTIN (00351662162019), expiration date (300101), lot number (123456), and a unique serial number. The label indicates the product is prescription only (RX ONLY).*

FDA Label Image

Carton (51662 1620 2 Carton Labeling)

Packaging label for Naloxone HCl Nasal Spray 4 mg intranasal spray by Perigo, a two-pack box. The label includes usage instructions for opioid overdose, directions, and a barcode. The label highlights that the product contains two single doses of 4 mg/0.1 mL nasal spray for emergency use only, with clear emphasis on the product's strength and nasal spray format.*

FDA Label Image

Back (51662 1620 2 Individual Package Label Back)

Label of Naloxone HCl Nasal Spray 4 mg, a nasal spray for prescription use. The label includes storage instructions, manufacturer information (Perrigo, Israel), and a barcode with NDC 45802-811-00. It states one spray per device and emphasizes use for known or suspected opioid overdose in adults and children.*

FDA Label Image

Front (51662 1620 2 Individual Package Label Front)

NALOXONE HCl Nasal Spray 4 mg packaged in a clear plastic blister. The product name and strength are printed on the label beneath the spray device. The label indicates the nasal route with instructions specifying use in the nose only. Manufacturer or labeler details are not visible.*

FDA Label Image

Serialized (51662 1620 2 Serialized Labeling)

A label featuring a GS1 data matrix barcode and application identifier data including (01) Global Trade Item Number, (17) expiration date, (21) serial number, and (10) lot number. The label states "See manufacturer's package insert" and shows distribution information for HF Acquisition Co., LLC in Mukilteo, WA 98275. The label includes a vertical "RX ONLY" statement.*

FDA Label Image

Clinical P 1 (Clinical 1)

Table presenting mean pharmacokinetic parameters (CV%) for Naloxone following various doses of Naloxone HCl nasal spray and intramuscular injection in healthy subjects. Parameters include tmax, Cmax, AUCt, AUC0-inf, t1/2, and dose normalized relative bioavailability (BA) compared to intramuscular injection, across multiple dose regimens and concentrations.*

FDA Label Image

Clinical P2 (Clinical 2)

Two line graphs showing mean plus standard deviation of plasma concentration of Naloxone over time following different administration methods. Graph (a) shows Naloxone plasma concentration from 0 to 6 hours postdose for 2 mg and 4 mg nasal sprays, administered in one or both nostrils, and 0.4 mg intramuscular injection. Graph (b) zooms in on the first hour postdose, displaying rapid plasma concentration changes for the same dosing and administration routes.*

FDA Label Image

I1 (Instruction 1)

An instructional illustration showing a pair of hands peeling open a rectangular foil pouch, presumably containing a nasal spray product. No text or additional product details are visible in the image.*

FDA Label Image

I2 (Instruction 2)

An instructional illustration of a hand holding a nasal spray device labeled with its components. The *

FDA Label Image

I3 (Instruction 3)

An instructional black-and-white illustration showing a person lying down while another hand inserts a nasal spray into one nostril. The hand supports the head and manipulates the nasal spray for administration through the nasal route.*

FDA Label Image

I4 (Instruction 4)

An instructional line drawing showing a hand holding a nasal spray device with the nozzle inserted into a nostril, demonstrating the spray being administered into the nose.*

FDA Label Image

I5 (Instruction 5)

An instructional diagram showing a person lying on their side in a recovery position. Labels indicate the hand supports the head and the knee stops the body from rolling onto the stomach, illustrating proper positioning likely related to use of a nasal spray product.*

FDA Label Image

Or1a (Ori 1a)

Naloxone HCl Nasal Spray 4 mg carton label showing important use instructions and product details. The label states the spray is for nasal use only, contains two 4 mg intranasal doses, and is used for known or suspected opioid overdose in adults and children. Instructions on identifying overdose symptoms and administering the spray are included. The labeler mentioned is Perrigo.*

FDA Label Image

1bb (Ori 1bb)

NALOXONE HCl Nasal Spray 4 mg/.1 mL intranasal spray carton. The label shows two 4 mg doses per box with instructions for use, storage conditions, and emergency steps illustrated. It is manufactured by Perrigo in Israel and distributed by HF Acquisition Co LLC, DBA HealthFirst. Packaging includes barcode and product information details.*

FDA Label Image

Ori1aa (Ori1aa)

NALOXONE HCl Nasal Spray 4 mg packaging label displaying a two-pack box for intranasal use. The label includes the product name and strength prominently, usage instructions emphasizing use only for opioid overdose, and manufacturer Perrigo noted. An adjacent panel provides a quick start guide with step-by-step illustrated instructions for identifying an overdose and administering the nasal spray.*

FDA Label Image

Ori1b (Ori1b)

NALOXONE HCl Nasal Spray 4 mg packaging label by HF Acquisition Co LLC, DBA HealthFirst. The label indicates 4 mg/0.1 mL intranasal spray, with two single doses per box. Instructions and warnings are included, along with storage information and manufacturer details, Perrigo. Barcode and contact information are present.*

FDA Label Image

Q1 (Quick 1)

An instructional illustration showing a person kneeling next to another lying on their back. The kneeling person appears to check the other individual's airway or breathing by tilting the head back and lifting the chin, commonly associated with first aid or emergency response procedures.*

FDA Label Image

Q2 (Quick 2)

NALOXONE HCl Nasal Spray 4 mg/.1mL packaging label displays usage instructions and dosage information. The label includes the proprietary and generic name, strength, dosage form, and the labeler HF Acquisition Co LLC, DBA HealthFirst. An illustration shows hands peeling back the label, emphasizing the instructions.*

FDA Label Image

Q3 (Quick 3)

An instructional illustration showing three steps for using a nasal spray device. The top panel highlights parts of the device labeled 'Nozzle' and 'Plunger.' The middle panel shows a person lying down receiving the nasal spray, with hands holding the device near the nose. The bottom panel depicts the spray being administered into a nostril with spray droplets visible.*

FDA Label Image

Q4 (Quick 4)

Illustration showing a person lying on their side with one hand supporting their head and one knee positioned to prevent the body from rolling onto the stomach. Labels indicate the hand supports the head and the knee stops the body from rolling onto the stomach.*

FDA Label Image

Structure (Structure)

Chemical structure of naloxone hydrochloride, showing its molecular framework with hydroxyl groups, nitrogen, oxygen atoms, and the attached hydrochloride (HCl) component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.